Abstract：Objective: To observe the efficacy of SRM-IV vertigo diagnosis and treatment system in the treatment of benign paroxysmal positional vertigo (BPPV). Methods: A total of 154 patients with BPPV in the hospital were enrolled from July 2023 to July 2024, and were divided into control group (manipulative reduction treatment) and instrument reduction group (SRM-IV vertigo diagnosis and treatment system) by random number table method. The therapeutic effect, vertigo degree [Dizziness Handicap Inventory (DHI)], vestibular function [Vestibular Activities of Daily Living (VADL), Vestibular Symptom Index (VSI)] and balance function [Berg Balance Scale (BBS)] before and after treatment were compared between groups, and the incidence rate of adverse reactions and occurrence of residual dizziness (RD) within 1 month of follow-up were counted. Results: The total effective rate in instrument reduction group was higher than that in control group (P<0.05). After treatment, the scores of VADL,DHI and VSI scales in the two groups were decreased, the BBS score in both groups was risen, and the difference value before and after treatment in instrument reduction group was significantly greater than that in control group (P<0.05). there was no statistical difference in the incidence rate of adverse reactions between groups (P>0.05). Within 1 month of follow-up, the incidence rate and duration of RD in instrument reduction group were significantly lower or shorter compared to control group (P<0.05). Conclusion: SRM-IV vertigo diagnosis and treatment system has significant efficacy in the treatment of BPPV, and it can effectively improve the vertigo degree, vestibular function and balance function, and reduce the occurrence of RD symptoms, and it has good safety.
2025, Vol. 31 
冀公网安备13080202000786号